 |
|
|
|
June 2000 Cover
|
|
Gilead Sciences announced that a mid-stage trial of its experimental AIDS drug tenofovir indicates that it reduced the viral load of patients who are resistant to other drugs by seven times. Tenofovir is a nucleotide
analog, which blocks reverse transcriptase. The 48-week Phase II study involved 189 patients who had taken antiretroviral therapy for a number of years. The researchers said that patients taking 300 mg. doses of the once-daily
drug saw an average seven-fold reduction in viral load, while individuals taking lower doses saw lower decreases.
Editor's Note: from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
